Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials

J Eur Acad Dermatol Venereol. 2020 Jan;34(1):e21-e24. doi: 10.1111/jdv.15866. Epub 2019 Aug 30.

Authors

R Bissonnette¹, P Fernández-Peñas^{2

3}, L Puig⁴, A M Mendelsohn⁵, S J Rozzo⁵, A Menter⁶

Affiliations

¹ Innovaderm Research, Montreal, QC, Canada.
² Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia.
³ Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
⁴ Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
⁵ Sun Pharmaceutical Industries, Inc., Princeton, NJ, USA.
⁶ Division of Dermatology, Baylor Scott & White, Texas A&M College of Medicine, Dallas, TX, USA.

PMID: 31403725
DOI: 10.1111/jdv.15866

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Cardiovascular Diseases / complications*
Humans
Placebos
Psoriasis / complications
Psoriasis / drug therapy*
Randomized Controlled Trials as Topic

Substances

Antibodies, Monoclonal, Humanized
Placebos
tildrakizumab

Grant support